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Abstract Because of the emergence of dried blood spots
(DBS) as an attractive alternative to conventional venous
plasma sampling in many pharmaceutical companies and
clinical laboratories, different analytical approaches have
been developed to enable automated handling of DBS
samples without any pretreatment. Associated with selec-
tive and sensitive MS–MS detection, these procedures give
good results in the rapid identification and quantification of
drugs (generally less than 3 min total run time), which is
desirable because of the high throughput requirements of
analytical laboratories. The objective of this review is to
describe the analytical concepts of current direct DBS
techniques and to present their advantages and disadvantages,
with particular focus on automation capacity and commercial
availability. Finally, an overview of the different biomedical
applications in which these concepts could be ofmajor interest
will be presented.
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Introduction
Although biological analysis is usually performed using
plasma obtained by venipuncture, the use of dried blood spots
(DBS) has grown in popularity in the clinical and pharma-
ceutical communities over the past decade as an alternative
sampling procedure. The numerous advantages of the DBS
sampling process can be summarized as follows:
& Ease – DBS is less invasive than conventional whole
blood, plasma, or serum sample collection [1–3]
because the blood can be collected after a small finger
prick (or heel prick for pediatric applications). Because
of the ease of collection, DBS can be obtained in a non-
hospital environment by minimally trained technicians
or even at home by the patients themselves [4–6].
Moreover, the DBS process does not require use of an
anticoagulant, or plasma separation, which limits the
number of manipulations.
& Small sampling volume – less than 20 μL is usually
spotted on to filter paper, whereas a minimum volume of
0.5 mL is required with conventional venous sampling.
& Cost-effective process – the cost of shipping/storage of
filter paper cards is substantially reduced, because the
DBS samples can be stored at room temperature
without the use of dry ice [7].
& Analyte stability – it has been reported in numerous
publications that DBS that have been stored over many
months (even years) at ambient temperature are just as
stable as plasma samples that were stored at −20 °C [8, 9].
& Improved safety – during drying, most of the patho-
genic agents are deactivated on the filter paper, which
reduces the risk of infection to a minimum. Similarly,
transfer of blood material on to a filter paper card is
considered to have a low infection risk [4, 10, 11].
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These advantages make the DBS procedure a patient-
friendly tool for blood collection, especially for problematic
and vulnerable patient populations [12–14]. The ease of the
process can also help in the recruitment of subjects (human
and animal) for preclinical and clinical studies [15–17] and
can significantly reduce the cost of these studies [18].
Interesting reviews covering these different aspects were
recently published to promote the use of DBS in bioanalysis
[19, 20].
The first biomedical application of DBS on filter paper
dates back to 1963 when Professor Robert Guthrie
introduced this alternative sampling method for detection
of phenylketonuria in the newborn population [21].
Detection of L-phenylalanine was based on a microbiological
test that was sufficiently sensitive but with low analytical
throughput. In the early 1990s, the development of PCR and
immunoassays, including ELISA, RIA, or FIA, enabled the
detection of DNA, viral RNA, antibodies, and hormones
from DBS with an acceptable waiting time that was suitable
for high-throughput analyses [22–27]. These advances
extended the scope of applications of the DBS to the
detection of different biomarkers in epidemiological studies
[11, 28].
At the same time, the detection of small pharmaceutical
compounds was investigated by coupling liquid chroma-
tography (LC), as separation technique, with UV or
fluorescence detection. Although LC was, in general, more
selective than immunoassays by separating the compounds
of interest from the matrix before detection, the initial
methods based on DBS–LC–UV were limited to the
quantification of drugs at high concentrations [29–31],
because of the poor sensitivity.
In fact, one limitation of DBS analysis is that the small
volume of biomatrices spotted implies the need for highly
sensitive techniques for detection and quantification of
molecules present at concentrations below 1 ng mL−1 [19].
A new generation of mass spectrometers (MS), particularly
triple-quadrupole spectrometers (MS–MS) operating in
MRM mode, have greatly improved sensitivity, which
enables analysis of pharmaceuticals in the low therapeutic
range [32]. Therefore, many studies have recently been
published showing interest in coupling DBS samples with
LC–MS–MS for measurement of therapeutic agents or
biomarkers in clinical and research settings [33–37].
Before detection, the analytes must be extracted from the
DBS to be more compatible with the analytical technique
(for example, immunoassays or LC–MS–MS). Thus, an
extraction is usually performed in off-line mode using a
mixture of aqueous and organic solvents. This pretreatment
step requires time and manipulation by technicians and can
become problematic if the number of samples is large.
Interestingly, the implementation of DBS support in
pharmaceutical companies in the last five years has led to
the development of novel techniques for handling this new
support before the analysis. This review will, therefore,
highlight the recent developments that enable direct
analysis of DBS samples either by direct insertion into
conventional LC–MS–MS systems or by direct ambient
extraction/ionization with subsequent MS–MS detection.
Finally, an overview of the different biomedical applications
will be presented.
Analytical concepts
On-line DBS
Integration of DBS with LC–MS is generally performed by
solvent extraction, which ensures transfer of the analytes
from the filter paper into an injectable solution that is
compatible with LC, as discussed above. Emphasis on DBS
sampling, especially in pharmaceutical analysis, has led to
the development of novel techniques that enable high-
throughput analysis. In a recent report, Déglon et al.
described a novel concept that enabled on-line desorption
of filter paper into an LC–MS system without any sample
pretreatment [38]. For this purpose, a stainless steel
desorption cell compatible with LC capillaries was
designed to integrate the filter paper containing the dried
spot. The behavior of the DBS during dynamic desorption
(ensured by application of a constant flow rate) was also
investigated to determine the kinetics and the efficiency of
analyte desorption and their dependence on experimental
conditions such as solvent and the flow rate. Experiments
have shown that the type of solvent can selectively affect
desorption output. As shown in Fig. 1, use of an aqueous
solution led to complete desorption of analytes and matrix
components, for example hemoglobin and proteins, which
were monitored using MS–MS and UV–visible spectroscopy,
respectively. Interestingly, use of organic solvents such as
ACN or MeOH led to contrasting results—only the analyte of
interest was monitored and the matrix components were not
detected. This was in agreement with the color of the filter
paper, which was maintained after organic desorption. In
another study, Thomas et al. showed that selective desorption
was applicable to a wide range of polarity compounds, for
example hydrophobic and hydrophilic drugs and their phase I
and II metabolites [15]. These results demonstrated that filter
paper can not only be regarded as a biofluid support. Indeed,
the intrinsic properties of cellulose have to be considered
when developing sample preparation or investigating novel
approaches, for example the development of selective
chemical or affinity interactions on the filter paper. In this
case, percolation of organic solvents through the filter paper
induced protein precipitation “on support,” which enabled
selective desorption of small molecules, for example drugs
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and pharmaceutical compounds. Because of the well-known
ion suppression encountered with atmospheric pressure
ionization sources such as ESI, the ability to eliminate
matrix effects without any sample preparation can be
particularly beneficial when LC–MS analysis is performed.
Post-column infusions have confirmed that this experimental
design is promising in reducing or avoiding matrix effects,
compared with conventional analysis of plasma. As illustrated
in Fig. 1, use of an aqueous desorption mobile phase (MP)
can lead to rapid clogging of analytical systems, the risk of
matrix effects, and the need to change chromatographic
columns frequently.
The kinetics of compound desorption have been inves-
tigated, and they were dependent on the flow rate and cell
geometry. In the first test of cell geometry (in which a
10 mm i.d. filter paper was used), a flow rate of
0.25 mL min−1 was shown to give complete desorption
after 5 min. Reduction of dead volume is particularly
important to reduce desorption time to a few seconds while
maintaining a low flow rate (0.1 mL min−1). However, this
reduction implies a concomitant decrease in the size of the
DBS used, and therefore in sensitivity, because, proportionally,
a lower volume of blood will be desorbed.
The fact that desorption was performed with an organic
solvent required the polarity of the MP to be adjusted using
an additional pump (delivering aqueous MP) after desorption
to ensure good trapping of the analyte on the reversed-phase
column and to avoid compound dispersion. Therefore,
focusing of the compounds can be performed on a trapping
column in a column-switching setup or directly on the
analytical column (because of very low desorption of the
contaminants).
This concept was recently automated by Déglon et al.
[39]. As illustrated in Fig. 2A, the developed prototype was
based on an automated rotating plate machined to host
multiple wells in which filter paper can be placed manually.
Next, an automatic clamp that contains two pistons was
programmed to sequentially ensure locking of the well
positions (followed by the desorption step) and was
synchronized with an LC–MS–MS system. This system
setup enabled many DBS samples to be analyzed. Further-
more, Thomas et al. demonstrated that reduction of the flow
rate to a few μL min−1 with the automated system gave a
desorption profile that was very close to an infusion profile,
which enabled MS acquisition over several minutes [40].
Based on the selectivity of the process discussed above, this
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Fig. 1 MRM chromatograms (top) and associated UV–visible spectra (bottom) obtained after on-line extraction with H2O (left) and ACN (right) of
DBS samples spiked with saquinavir at 250 ng mL−1. Pictures of DBS samples after extraction are incorporated in the MRM chromatograms
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approach was applied in a lipidomic approach for direct MS
analysis of dried spots without any sample preparation or
chromatographic separation (see the section “Biomarkers
identification”).
In parallel, the robot industry has recently developed
automatic systems for on-line DBS analyses [41, 42].
Prolab Instruments recently presented a commercially
available solution called SCAP DBS based on the principles
discussed above. In their configuration, an automatic clamp
(with different available i.d. sizes) enables direct desorption of
DBS integrated to a column-switching system with the
presence of an auxiliary pump for dilution of the desorption
MP [43]. The setup works directly on the DBS card without
the previous punch-out step because desorption of the blood
spot is ensured by the on-spot locking of the clamp, as
shown in Fig. 2B. Furthermore, this system is combined with
the versatile CombiPal autosampler for successive handling
of multiple DBS cards. In this configuration, a desorption of
0.5 min (for a total run time of less than 4 min) was shown to
be a good compromise between sensitivity and extraction
efficiency.
Compared with off-line extraction, which dilutes the
analyte, a remarkable advantage of on-line DBS procedures
is the efficient desorption of the compounds of interest
directly into the analytical systems; it is therefore a non-
diluting procedure [44]. Recent applications based on
automated on-line DBS analysis coupled to LC–MS–MS
systems (in MRM mode) have enabled full validation of
this technique using different pharmaceutical probes, for
example oseltamivir [43], flurbiprofen and its phase I
metabolite [39], and six tyrosine kinase inhibitors (data
not given). Good accuracy and precision (<15%) have been
obtained for these compounds, and the limit of quantification
is as low as 1 ngmL−1. For these automatic systems carryover
is low; this is explained by the cleanup position of the clamp
after DBS extraction. The different aspects of the techniques
that were discussed in this section are summarized in Table 1.
Surface sampling probe
Compared with the on-line DBS approach in which the
analytes are desorbed from the filter paper by percolation of
a solvent through the blood spots, a second approach, called
surface sampling probe (SSP), extracts the compounds of
interest from a surface by connecting this surface with a
confined liquid stream dispensed by an appropriate probe
[45]. The stream is both brought to the surface then carried
on to the conventional LC–MS device or directly infused
Stand
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Fig. 2 Illustration of two automated on-line DBS instruments, the automated on-line DBS prototype developed by Déglon et al. (A) and the
SCAP solution commercialized by Prolab (B), and their respective integration into conventional LC–MS–MS systems
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into the MS ionization source. Two different types of SSP
have been published—the liquid microjunction-surface
sampling probe (LMJ-SSP), which can be applied to
extraction of analytes from the surfaces of hard and
nonporous materials like glass or metal, and the sealing
surface sampling probe (SSSP), by use of which porous
surfaces, including most filter papers, can also be analyzed.
SSSP
Direct liquid extraction based on SSSP is part of an
emerging area in MS that combines ambient extraction of
analytes contained in or on surfaces with ESI or APCI
ionization. Initially, SSSP was developed to couple cost-
effective thin layer chromatographic (TLC) separation with
selective and sensitive MS detection. Luftmann reported an
original device that enabled on-line transfer of TLC-separated
compounds into a solvent stream toward MS [46]. Based on
this proof-of-concept, Camag commercialized a TLC–MS
interface that had the same characteristics as the Luftmann
plunger [47]. However, unlike the latest development of the
Luftmann plunger in terms of automation [48], Camag did
not include automatic positioning of the plunger above the
sample foil in its first version.
More recently, Van Berkel et al. extended the original use
of the Camag TLC–MS interface for DBS analysis by
replacing the TLC plates with filter paper sheets containing
DBS samples [45]. Briefly, the Camag interface used for
this approach comprised a stainless steel plunger (also
called an extraction head) with a solvent inlet and an outlet
capillary and a ring-shaped cutting edge at its end face
(Fig. 3A). Before analysis, the DBS samples were manually
positioned under the extraction head assisted by a laser
pointer, and the plunger was activated and pressed on the
paper sheet by compressed air. The cutting edge severed the
filter paper and formed a tight seal with the paper. The
extraction solvent, which was delivered by a conventional
LC pump, entered the plunger through the inlet capillary,
dissolved the analytes contained in the DBS, and left
through the outlet capillary before ESI–MS detection. To
avoid any clogging of the instrument, the outlet capillary
was protected by a filter frit. A six-port valve enabled
isolation of the solvent flow from the MS interface when
the plunger was in the retracted position. Thus, the capacity
of the Camag TLC–MS equipment to directly extract drugs
from DBS previously spotted on filter paper was demon-
strated for the first time. For these tests, sitamaquine and
acetaminophen were used as probes to evaluate the
reproducibility and the quantitative aspects of the system.
Experiments were conducted using MeOH as extraction
solvent at a flow rate of 0.2 mL min−1 through a 4 mm i.d.
plunger for a duration of 60 s, and the extraction was
followed by direct MS detection in MRM mode. To
eliminate carryover, the system was washed for 60 s
between each DBS by sampling a blank zone on the filter
paper. The spot-to-spot analysis time was approximately
3 min, which includes the DBS extraction and cleanup
steps. The reproducibility of the extraction was excellent,
carryover was low when using washout, and good
quantification was achieved over the concentration ranges
10 to 10,000 ng mL−1 and 50 to 5000 ng mL−1 for
sitamaquine and acetaminophen, respectively. Unfortunately,
the effect of the matrix was not investigated in this study.
In parallel studies, Abu-Rabie et al. tested the Camag
TLC–MS interface in combination with LC separation
before MS detection [49]. On the basis of the same LC–
ESI–MS–MS method, they compared traditional off-line
DBS extraction and both modes of the Camag TLC–MS
(with or without the LC column). For these experiments,
different solvents, flow rates, and extraction times were
tested in the analysis of DBS for various pharmaceuticals.
Extraction solvents giving good sensitivity were usually a
mixture of aqueous buffer and MeOH or ACN. Because of
the lack of a second LC pump that could deliver H2O to
Table 1 Evaluation of the different techniques that enable direct DBS analysis coupled with MS–MS detection
Criteria Direct DBS analysis techniques
Online DBS (SCAP) SSSP (TLC–MS) LMJ-SSP (LESA) Paper spray DESI (Omni Spray)
LC separation-compatible Yes Yes No No No
Sensitivity **** **** ** ** **
Quantitative performance **** **** ** * *
Automation/throughput *** * (***)a **** * *
Commercial availability Yes Yes Yes No Yes
Cost ** * *** n.d. *
a Available soon
Criteria evaluation is based on four levels corresponding to low (*), medium (**), high (***), and very high (****). For cost evaluation, one *
corresponds to a price going from 10,000 to 50,000 $.
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focus the analytes ahead the analytical column, a higher
flow rate was applied (between 0.5 and 1 mL min−1) during
a very short period to obtain sufficient extraction efficiency.
Under these conditions, the chromatographic peak shape
was acceptable up to an extraction time of 5 s, after which it
became increasingly broad. Use of short (i.e. 50 mm) LC
columns with medium-sized (3 μm) particles enabled the
application of high flow rates without generating excessive
backpressure in the plunger. Despite the use of a very short
extraction period, improved sensitivity was achieved
compared with the off-line extraction mode, with which
only part of the extraction solvent could be injected, which
implies an important dilution factor. Bioanalytical valida-
tion of the TLC–MS interface in LC–MS–MS mode was
performed on sitamaquine and acetaminophen. According
to international validation criteria, acceptable accuracy,
precision, and linearity were achieved over the ranges 5 to
1000 ng mL−1 and 50 to 50,000 ng mL−1 for sitamaquine
and acetaminophen, respectively. However, a substantial
amount of carryover was observed; this required manual
cleaning of the system.
Subsequently, Heinig et al. presented a TLC–MS
interface that was integrated into a column-switching LC–
MS–MS system that enabled quantification of drugs in
DBS at concentrations as low as 50 pg mL−1 [44]. The
increase in sensitivity compared with the work discussed
above was because of the combination of a longer
extraction step (typically 45 s) with focusing of analytes
ahead of the trapping column ensured by a tee connector
and a second LC pump delivering high H2O flow rate (see
the section “On-line DBS”).
The SSSP technique, by means of the commercial TLC–
MS interface, has proved to be a promising method with
sufficiently reproducibility and sensitivity with a suitable
DBS card
DBS sample
Pipette tip
Extraction 
solvent
Nanospray 
chip
90°
MS analyzer
Cutting edge
Extraction 
plunger
DBS card
DBS sample
from LC pump to MS or LC-MS
A) 
B) 
Fig. 3 Schematic views of the extraction head of the Camag TLC–MS interface (A) and the TriVersa NanoMate of Advion operating in LESA
mode (B) for the direct extraction of DBS samples with subsequent MS detection
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delay for high-throughput DBS analysis (Table 1). Intrinsi-
cally, the total run time using LC separation was similar to
the run times obtained by use of SCAP technology [43].
However, the TLC–MS interface suffers from an important
lack of automation, because three manual operations (DBS
positioning below the extraction head, activation of the
plunger, and the six-pore valve switch) were required
before the start of an analysis. To handle larger sample
numbers by feeding the DBS card automatically into the
extraction device, Camag is currently developing an
automated system for routine application which should be
commercially available during 2011 [50].
LMJ-SSP
In the LMJ-SSP approach, the analytes are extracted from
the surface by connecting the surface to a wall-less liquid
microjunction dispensed by an appropriate probe. Unlike
the SSSP technique, in which the plunger forms a sealed
contact with the sampling surface, the probe used in the
LMJ-SSP is positioned an appropriate distance from the
surface (typically 0.2 mm), and a liquid microjunction is
then formed by enabling the liquid from the end of the
probe to extend from the probe to the surface [51]. Because
of the dynamic solvent flow and the lack of sealing, the
current LMJ-SSP probe is unsuitable for extraction of
porous surfaces. In the analysis of DBS, the liquid micro-
junction will not remain in contact with the filter paper
because of its high absorption capacity. However, an
interesting alternative which overcomes this limitation is
use of the Advion TriVersa NanoMate system operating in
LESA mode in which a static microjunction can be
performed. As depicted in Fig. 3B, the TriVersa NanoMate
is constituted of two distinct parts: a robotic arm with
adequate conductive pipette tips ensuring that samples are
loaded, and a chip that contains microfabricated nozzles to
generate a nanoelectrospray of the liquid samples. Before
the surface sampling process, the robotic arm picks up a
conductive pipette tip and moves above the well that
contains the extraction solvent. A few microliters (usually 1
to 5 μL) are loaded in the pipette tip and the arm
automatically goes to the desired extraction zone (DBS).
The arm is then lowered to an appropriate distance from the
target spot, and part of the extraction solvent is dispensed
on to the sample surface to form a static liquid micro-
junction between the end of the pipette tip and the surface.
Immediately thereafter, the solution is aspirated back into
the tip and is finally sprayed through a nanospray nozzle for
subsequent MS detection.
Kertesz and Van Berkel published an interesting paper on
the feasibility of this concept [52]. Based on the NanoMate
TriVersa operating in LESA mode, they performed quanti-
tative analyses of pharmaceuticals from three different
surfaces—MALDI plates, thin tissue sections, and DBS.
For the DBS, quantitative investigation was performed
using sitamaquine in a 4-mm DBS using a mixture of ACN,
MeOH, and an aqueous buffer as the extraction solvent. In
this experiment, 4 μL was loaded in the pipette tip and
3 μL was dispensed on to the DBS samples before
nanoESI–MS–MS detection; this led to a total run time of
approximately 2 min per sample.
Quantitative performance was also investigated by the
authors. in accordance with international guidelines, LOQ
was set to 100 ng mL−1 (<15% precision, <15% accuracy).
An important bias (77%) and poor precision (98%) were
observed at lower concentrations (10 ng mL−1) even though
a deuterated internal standard was used. Quantitatively, on-
line DBS or SSSP could reach an LOQ that was 100 times
lower [39, 44]. This can be explained by the use of dynamic
extraction flow applied to the DBS compared with the static
transfer that occurred in the LMJ delivered by the LESA
pipette tip. Moreover, the lack of an LC setup to ensure
focusing of the desorbed analytes contributes to limiting the
sensitivity.
However, LMJ-SSP with the TriVersa NanoMate has two
principal advantages compared with the Camag TLC–MS
interface. First, it is a carryover-free approach because the
pipette tip and nanospray nozzle are changed between each
analysis, which means that no cleanup step is required.
Second, the procedure is automated, which enables high-
throughput analysis.
Although the Triversa NanoMate combines the advantages
of a nanoESI source with direct extraction of a sampling
surface, the cost of this system is 10 times higher than the
instrument commercialized by Camag (Table 1).
Desorption electrospray ionization and paper spray
In this section, we will discuss two ambient ionization MS
(AIMS) methods used for direct analysis of the DBS—
desorption electrospray ionization (DESI) and paper spray
(PS). The AIMS techniques enable ionization of untreated
samples in an open environment [53]. No sample pretreat-
ment is required and analysis is very fast with the time scale
limited to the time needed to present the sample to the MS
[54]. Because of these features, AIMS methods are
particularly suitable for high-throughput analysis.
Among recent AIMS techniques, DESI developed by
Cooks et al. in 2004 is regarded as the initial technique.
Briefly, the main DESI mechanism can be describe as
“droplet pick-up” [55] (Fig. 4A). In this process, ions are
generated from the sampling surface by bombardment with
charged micro-droplets through the atmosphere. The impact
of the spray causes the formation of a microscopic layer of
liquid on the sample surface, which results in dissolution of
the analytes. This process is directly followed by desorption
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by momentum transfer when additional droplets collide
with the liquid layer and force the dissolved analytes into
the gas phase as micron-sized droplets [56]. After their
evaporation, which is assisted by a standard heated
capillary extending from the MS inlet, the charged droplets
produce free gas-phase ions when entering the MS
interface.
Recently, Wiseman et al. experimented with DESI
methodology for direct analysis of pharmaceutical com-
pounds in DBS [57]. For this purpose, sitamaquine,
terfenadine, and prazosin were chosen as probes and
verapamil was used as the common internal standard. In
these preliminary experiments, DBS were cut into strips
and secured to a glass slide, and a commercial DESI source
(Prosolia Omni Spray 1D Ion Source) was coupled with an
MS–MS instrument. Each DBS was therefore analyzed by
scanning across the DBS surface at a rate of 200 μm s−1,
which resulted in a peak 40 s wide on the ion chronogram.
The solvent flow rate delivered by the sprayer was also
investigated and was set at 15 μL min−1 as a good
compromise between sensitivity and cross-contamination.
Good signal intensity and stability were obtained when
solvent extraction was performed with 80:20 ACN–H2O
containing 0.1% formic acid.
Under these conditions, full validation was performed on
sitamaquine in the concentration range from 10 to
10,000 ng mL−1. Unfortunately, accuracy and precision of
the values for QC samples at 10 and 40 ng mL−1 were
k VSolvent
MS interface
Nebulizer gas 
(N2)
k V
MS analyzer
10 µL MeOH/H2O
A) 
B) 
Fig. 4 Schematic representations of the DESI source (A) and the PS configuration (B) applied to direct MS analysis of the DBS samples
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outside the pre-defined performance criteria (>15%). Thus,
the quantitative performance of DESI was similar to that of
LMJ-SSP using LESA (see the section “LMJ-SSP”). The
authors also investigated the ion-suppression effect. They
demonstrated that the concentration of IS added (between
500 and 2500 ng mL−1) led to suppression of the
sitamaquine response by a factor of ten. This ion suppres-
sion explains the quantification problems that arose at low
concentration.
An alternative to DESI for direct DBS analysis is the
PS approach. This technique enables ions to be generated
from a liquid sample loaded on to a piece of filter paper
by applying a high potential to the wet paper [54].
Indeed, the wet paper is conductive and the network of
cellulose fibers forms microchannels for liquid transport.
As shown in Fig. 4B, the high potential applied between
the base of the paper (previously cut into a triangular
shape) and the MS inlet generates an electric field that
induces charge accumulation at the apex of the paper
triangle, which faces the MS inlet. Similar to ESI,
Coulombic forces fracture the liquid to form charged
droplets, which undergo desolvation and generate dry
ions. On the basis of this mechanism, Liu et al. recently
developed a method that enabled direct analysis of
atenolol from a 0.4-μL DBS previously spotted on to
filter paper [58]. Briefly, triangular paper (10 mm long and
5 mm wide at its base) containing the DBS sample was
held by a copper clip in front of the MS inlet at a distance
of 3 mm. Next, 10 μL 1:1 MeOH–H2O was applied near
the base of the paper triangle to wet the paper and extract
the analytes, and a 4.5-kV potential was applied while the
mass spectra was recorded in MRM mode. The results
showed the LOD was 1 μg mL−1 for atenolol; no other
quantitative aspects were investigated. As previously
described, use of an organic solvent (MeOH in this
instance) enabled the blood cells to remain on the filter
paper, whereas dissolved molecules were carried to the
paper tip and released in the spray.
Wang et al. showed the quantitative potential of this
technique by quantifying imatinib in a 0.4-μL DBS in the
concentration range 62.5 to 4000 ng mL−1, with labeled
compound used as an internal standard [59]. Nevertheless,
full validation of this process must still be completed to
characterize the technique.
The AIMS methods, for example DESI and PS, are an
interesting alternative for direct DBS analysis, because the
procedure is relatively user-friendly and pretreatment-free.
However, the very small blood volume spotted (0.4 μL for
PS) and the lack of LC columns results in relatively low
sensitivity compared with other methods (Table 1). Moreover,
substantial ion suppression in the DESI approach limits
quantitative performance.
Applications
Although plasma sampling is still the gold standard in
pharmaceutical and clinical laboratories, DBS is becoming
increasingly accepted in biomedical applications, particularly
in pediatrics in the USA, where 95% of newborns are screened
for inborn metabolic disorders [60, 61]. As demonstrated by
recent publications, this alternative sampling procedure has
been successfully introduced for other applications, including
clinical investigations, TDM programs, and epidemiological
or surveillance studies [62]. Although these methods are
mainly based on off-line extraction of filter paper, promotion
Table 2 Representative MRM transitions of pharmaceuticals and
metabolites
Analyte MRM transitiona (m/z) Estimated LOQb
[ng mL−1]
Alprazolam 309→281 (35) 1.0
Amiodarone 646→58 (90) 0.5
Atracurium 358→206 (27) 0.5
Benzoylecgonine 290→168 (29) 1.0
Bupropion 240→131 (30) 0.5
Citalopram 325→109 (20) 1.0
Clopidogrel 322→212 (23) 0.5
Cocaine 304→182 (29) 1.0
Codeine 300→165 (50) 5.0
Dextromethorphan 272→128 (85) 1.0
Diazepam 285→193 (35) 10
Fentanyl 337→188 (35) 0.2
Flunitrazepam 314→268 (35) 5.0
Imatinib 494→394 (36) 1.0
Methadone 310→265 (20) 1.0
Midazolam 326→291 (37) 0.5
Mirtazapine 266→195 (35) 0.5
OH-midazolam 342→324 (31) 2.0
Omeprazol 346→198 (19) 0.5
Phenytoin 253→182 (20) 50
Prasugrel 374→206 (23) 0.2
Quetiapine 384→253 (35) 1.0
Risperidone 411→191 (35) 5.0
Saquinavir 671→570 (45) 2.0
Tacrolimus 821→768 (30) 5.0
Tramadol 264→58 (20) 0.5
Venlafaxine 278→260 (20) 5.0
Zolpidem 308→235 (35) 1.0
a The collision energy (eV) is indicated in parentheses
b Limits of quantification (S/N>10) estimated for 5 μL DBS samples
analyzed on a 5500 QTrap mass spectrometer in ESI mode. Extraction
was performed by use of automated on-line DBS followed by RP-LC
separation on a Kinetex C18 column (2.1 mm×50 mm, 2.7 μm i.d.)
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of the novel techniques discussed in this review will ensure
new opportunities in these fields. The next sections of this
review will present a non-exhaustive list of applications for
which direct and automated DBS analysis are suitable.
General unknown and target screenings
In biomedical applications in which rapid and comprehensive
analytical tools are required, for example in general unknown
screening (GUS) and target screening (TS), direct DBS
analysis may be an attractive solution because it combines a
friendly sampling process with sensitive and selectiveMS–MS
detection.
LC–MS–MS has, moreover, recently been applied to
GUS and TS strategies [63]; the capacity of direct DBS
analysis enabled simultaneous acquisition of different MS–MS
experiments increasing the information obtained in a single run
[64], and the development of novel bioinformatic tools that
ensure complex data mining [65].
Among the different direct DBS techniques discussed
above, on-line DBS and SSSP (i.e. the Camag interface)
combined with LC separation capacity, seem to be
particularly convenient for identification of compounds in
complex biomatrices. In our laboratory, we recently
developed a TS strategy that enabled the identification
and semi-quantification of 90 selected pharmaceuticals and
metabolites by automated on-line DBS LC–MS–MS, with a
run time of 10 min. Representative MRM transitions and
the estimated LOQ are listed in Table 2 and the complete
list is given in Electronic Supplementary Material Table S1.
All of the compounds of interest were tested using
automated on-line DBS with RP-LC separation before
MS–MS detection in ESI mode.
Preclinical study
With regard to the recent implementation of the DBS
sampling process in the pharmaceutical industry, it is
apparent that DBS are becoming increasingly important in
preclinical studies of drug metabolism and pharmacokinetics
(DMPK) [66]. In the early stages, drug candidates are tested
for ADME properties using small animal models, in which
amounts of biological material are often restricted [16]. Thus,
if a conventional sampling procedure is used (plasma), one
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Fig. 5 Typical workflow of a clinical study performed with the DBS
sampling process followed by on-line LC–MS–MS analysis (A). For this
trial, 50 mg flurbiprofen was orally administered to human volunteers
and DBS samples were collected over eight hours. Representative log
concentration–time profiles for flurbiprofen (triangles) and the OH-
flurbiprofen metabolite (squares), and the associated MRM chromato-
grams at two hours are presented (B)
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animal must be sacrificed for each experiment or time-point
in a kinetic study. With DBS sampling, multiple experiments
or time-points can be performed on the same animal, leading
to significant benefits in the 3Rs (reduction, refinement, and
replacement) in animal use [67]. Moreover, direct DBS
techniques now enable increased throughput of DBS
analysis; this is particularly appropriate in the pharmaceutical
industry, in which large numbers of drug candidates are
tested. For example, Roche laboratories have successfully
applied on-line DBS using SCAP technology to a study of
the pharmacokinetic of oseltamivir on rats [43].
Even though very few papers have been published focusing
on drugmetabolism studies based on DBS [68], Thomas et al.
demonstrated the possibility of highlighting phase I and II
metabolites of buprenorphine in rats after intraperitoneal
injection. In these experiments, buprenorphine, norbuprenor-
phine, and their respective glucuronides were simultaneously
monitored from 5-μL DBS samples [15].
Clinical study and therapeutic drug monitoring
If the ethical benefit of using DBS is clearly established for
animal use in preclinical studies, this less invasive sampling
mode can be easily applied to human clinical studies or
TDM investigations. As reviewed by Li and Tse, DBS–LC–
MS–MS has been increasingly used in this area for analysis of
a wide range of drug molecules, including antiretroviral,
immunosuppressant, antiepileptic, or antimalarial drugs [19].
Moreover, Glaxo Smith Kline regards DBS sampling as the
preferred sampling method for orally dosed compounds in
Phase I clinical trials [69]. Although all the DBS methods
discussed in this section are based on off-line extraction with
subsequent LC–MS–MS analysis, direct strategies, discussed
in this review, will certainly promote DBS analysis in clinical
laboratories. For example, Roche has successfully applied
the Camag TLC–MS interface to phase I determination of
drug candidates in human DBS samples [44].
Furthermore, this kind of strategy may be of important
benefit to clinical pharmacology in terms of ease of use for
medical staff and patient comfort. On the basis of these
considerations, an automated on-line DBS method for
pharmacokinetic study of flurbiprofen and its main metabolite
4-hydroxyflurbiprofen in human volunteers was developed at
the University Hospitals of Geneva to assess the activity of
cytochrome P450 2C9 (Fig. 5). The system was successfully
tested on over 500 real samples, demonstrating the good
competitiveness of the process compared with conventional
plasma LC–MS–MS analysis [39].
On-line DBS 
Direct infusion MS/MS
2 µL plasma
Statistical treatment (PCA) 
cluster formation
Interest phospholipids 
identification
Mouse
Phospholipidomic profile
Fig. 6 High-throughput phospholipidomic fingerprinting for evalua-
tion of disease biomarkers. For this purpose, 2 μL mouse plasma
previously spotted on filter paper was analyzed by MS–MS after
direct infusion using an on-line DBS process. Multiple MS–MS
experiments (neutral loss and precursor ion scans) were acquired for
simultaneous measurement of phospholipidic classes. Complex data
mining was performed by use of statistical tools to ensure sample
classification and to highlight the discriminated species
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Identification of biomarkers
The discovery of novel biomarkers is of major importance
for diagnosis of disease states, determination of prognosis,
and therapeutic response monitoring [70]. Over the past
decade, LC–MS–MS has become the key analytical
technique in the investigation of biomarkers by proteomic
and metabolomic approaches [71]. Regarding implementa-
tion of DBS in LC–MS–MS workflow (as discussed
previously), direct DBS analysis may be a novel means of
supporting the different stages in the biomarker pipeline
from discovery to the validation steps [72]. Preliminary
tests have demonstrated the feasibility of the analyses of the
enzymes and peptides spotted on filter paper using the
paper spray process [58]. Furthermore, Thomas et al.
developed an on-line DBS MS–MS strategy for high-
throughput fingerprinting of phospholipidome in athero-
sclerotic mice from 2 μL dried plasma that was desorbed
directly into the MS instrument without pre-treatment or LC
separation (Fig. 6) [40]. Based on multiple MS–MS
experiments and data mining, this study has enabled sample
classification between atherosclerotic and control mice and
highlighted several species that were significantly up and
down-regulated as a consequence of that pathology.
Conclusion
Over the past decade, DBS sampling has emerged as a
powerful alternative approach for clinical and pharmaceutical
analysis compared with the conventional venipuncture proce-
dure. The filter paper affords numerous advantages that range
from better shipment/storage logistics to a less invasive and
more ethical procedure. However, the lack of automation,
necessitating manual off-line extraction, could make this
procedure unsuitable for routine laboratories. The recent
developments highlighted in this review enable direct MS–
MS analysis of DBS samples (with or without previous LC
separation) and offer competitive solutions in terms of
throughput and sensitivity compared with the plasma proce-
dure. Furthermore, the marketing of automatic methods
indicates that some direct DBS methods are now mature and
can be easily implemented in analytical laboratories.
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